Curis (NASDAQ:CRIS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Curis (NASDAQ:CRIS) in a report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their target price on shares of Curis from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday, March 31st.

Curis Trading Down 7.5 %

Shares of Curis stock opened at $1.23 on Friday. The company has a 50-day moving average of $2.85 and a two-hundred day moving average of $3.74. Curis has a 12-month low of $1.19 and a 12-month high of $17.49. The stock has a market cap of $10.44 million, a PE ratio of -0.16 and a beta of 3.51.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.11. The firm had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. On average, sell-side analysts forecast that Curis will post -7.12 EPS for the current fiscal year.

Institutional Trading of Curis

A number of large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC purchased a new position in Curis in the 4th quarter valued at about $35,000. Millennium Management LLC lifted its stake in shares of Curis by 92.6% during the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 12,287 shares during the period. Focused Wealth Management Inc lifted its stake in shares of Curis by 9.5% during the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 5,138 shares during the period. Geode Capital Management LLC boosted its position in Curis by 27.3% during the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 17,820 shares during the last quarter. Finally, Alyeska Investment Group L.P. purchased a new stake in Curis in the 4th quarter worth approximately $607,000. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.